We are live on ! Find out more
ORTX

Orchard Therapeutics plc American Depositary Shares
ORTX

Delisted

ORTX was delisted on the 23rd of January, 2024.

Back to rankings

62 hedge funds and large institutions have $755M invested in Orchard Therapeutics plc American Depositary Shares in 2019 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 26 increasing their positions, 10 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

160% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 10

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

9% less funds holding

Funds holding: 68 → 62 (-6)

11% less capital invested

Capital invested by funds: $848M → $755M (-$92.5M)

28% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 18

Holders
62
Holders Change
-6
Holders Change %
-8.82%
% of All Funds
1.36%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
13
Increased
26
Reduced
10
Closed
18
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$22.7M
2
Federated Hermes
Federated Hermes
Pennsylvania
+$14.7M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$12.7M
4
Citadel Advisors
Citadel Advisors
Florida
+$9.01M
5
FCMI
Foresite Capital Management IV
California
+$7.78M

Top Sellers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
-$18.4M
2
VMI
VHCP Management III
New York
-$9.46M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$3.21M
4
MIM
Monashee Investment Management
Massachusetts
-$3.08M
5
PI
Putnam Investments
Massachusetts
-$2.25M
Name Holding Trade Value Shares
Change 		Change in
Stake
New York State Common Retirement Fund
26
New York State Common Retirement Fund
New York
$3.59M – – –
SI
27
Sofinnova Investments
California
$3.37M -$1.15M -8,206 -22%
EAM
28
Eventide Asset Management
Massachusetts
$3.21M – – –
GTC
29
Ghost Tree Capital
New York
$2.89M – – –
AA
30
ALPS Advisors
Colorado
$2.25M -$131K -939 -5%
Arrowstreet Capital
31
Arrowstreet Capital
Massachusetts
$2.06M +$1.85M +13,291 +330%
Point72 Asset Management
32
Point72 Asset Management
Connecticut
$1.92M +$2.25M +16,120 New
N
33
Nuveen
North Carolina
$1.89M +$2.21M +15,864 New
JPC
34
Jabodon PT Co
Nevada
$1.71M +$468K +3,350 +30%
Bank of America
35
Bank of America
North Carolina
$1.68M +$1.98M +14,153 New
Victory Capital Management
36
Victory Capital Management
Texas
$1.62M +$1.81M +12,964 +1,929%
BCP
37
Berylson Capital Partners
Massachusetts
$1.44M – – –
EU
38
Emory University
Georgia
$1.29M -$205K -1,471 -12%
TD Asset Management
39
TD Asset Management
Ontario, Canada
$1.27M +$271K +1,940 +22%
LCM
40
Laurion Capital Management
New York
$793K -$1.45M -10,412 -61%
PPA
41
Parametric Portfolio Associates
Washington
$781K +$204K +1,464 +29%
BFM
42
Boothbay Fund Management
New York
$604K +$709K +5,080 New
Northern Trust
43
Northern Trust
Illinois
$472K +$419 +3 +0.1%
OAM
44
Oxford Asset Management
United Kingdom
$421K +$220K +1,579 +80%
State Street
45
State Street
Massachusetts
$386K +$454K +3,250 New
Marshall Wace
46
Marshall Wace
United Kingdom
$334K +$41K +294 +12%
AC
47
Athanor Capital
New York
$277K +$126K +900 +63%
VEA
48
Virtus ETF Advisers
New York
$206K -$13.4K -96 -5%
Barclays
49
Barclays
United Kingdom
$183K +$129K +926 +150%
Goldman Sachs
50
Goldman Sachs
New York
$167K +$196K +1,404 New
1
2
3 4

ORTX Hedge Fund Activity: Q3 2019 in Review

62 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Orchard Therapeutics plc American Depositary Shares (ORTX) for Q3 2019, worth a combined $755M — down 11% from $848M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of ORTX and 13 opened new positions — a net loss of 5 holders — while 10 trimmed existing stakes and 26 added.

The largest buyer was Adage Capital Partners, adding an estimated $22.7M. The largest seller was Vivo Capital, exiting entirely with an estimated $18.4M sold.

  • 62 institutional investors held Orchard Therapeutics plc American Depositary Shares (ORTX) as of Q3 2019, down from 68 in Q2 2019.
  • Funds reported $755M of Orchard Therapeutics plc American Depositary Shares stock for Q3 2019, down 11% quarter-over-quarter.
  • 13 funds opened new Orchard Therapeutics plc American Depositary Shares positions in Q3 2019 and 18 closed out, a net change of -5 holders.
  • The largest Orchard Therapeutics plc American Depositary Shares buyer in Q3 2019 was Adage Capital Partners, an estimated $22.7M added.
  • The largest Orchard Therapeutics plc American Depositary Shares seller in Q3 2019 was Vivo Capital, an estimated $18.4M sold.

Based on aggregated 13F filings for Q3 2019.